Literature DB >> 14991069

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.

Elena Quaglino1, Simona Rolla, Manuela Iezzi, Michela Spadaro, Piero Musiani, Carla De Giovanni, Pier Luigi Lollini, Stefania Lanzardo, Guido Forni, Remo Sanges, Stefania Crispi, Pasquale De Luca, Raffaele Calogero, Federica Cavallo.   

Abstract

While much experimental data shows that vaccination efficiently inhibits a subsequent challenge by a transplantable tumor, its ability to inhibit the progress of autochthonous preneoplastic lesions is virtually unknown. In this article, we show that a combined DNA and cell vaccine persistently inhibits such lesions in a murine HER-2/neu mammary carcinogenesis model. At 10 weeks of age, all of the ten mammary gland samples from HER-2/neu-transgenic mice displayed foci of hyperplasia that progressed to invasive tumors. Vaccination with plasmids coding for the transmembrane and extracellular domain of rat p185neu followed by a boost with rp185neu+ allogeneic cells secreting IFN-gamma kept 48% of mice tumor free. At 22 weeks, their mammary glands were indistinguishable from those of 10-week-old untreated mice. Furthermore, the transcription patterns of the two sets of glands coincided. Of the 12,000 genes analyzed, 17 were differentially expressed and related to the antibody response. The use of B cell knockout mice as well as the concordance of morphologic and gene expression data demonstrated that the Ab response is the main mechanism facilitating tumor growth arrest. This finding suggests that a new way can be found to secure the immunologic control of the progression of HER-2/neu preneoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991069      PMCID: PMC351320          DOI: 10.1172/JCI19850

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  B cells inhibit induction of T cell-dependent tumor immunity.

Authors:  Z Qin; G Richter; T Schüler; S Ibe; X Cao; T Blankenstein
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

Review 2.  Immunoprevention of cancer: is the time ripe?

Authors:  G Forni; P L Lollini; P Musiani; M P Colombo
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

Review 3.  Cytokines, tumour-cell death and immunogenicity: a question of choice.

Authors:  P Musiani; A Modesti; M Giovarelli; F Cavallo; M P Colombo; P L Lollini; G Forni
Journal:  Immunol Today       Date:  1997-01

Review 4.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Authors:  M X Sliwkowski; J A Lofgren; G D Lewis; T E Hotaling; B M Fendly; J A Fox
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

5.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice.

Authors:  F Lucchini; M G Sacco; N Hu; A Villa; J Brown; L Cesano; L Mangiarini; G Rindi; S Kindl; F Sessa
Journal:  Cancer Lett       Date:  1992-07-10       Impact factor: 8.679

7.  Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.

Authors:  Elena Quaglino; Simona Rolla; Manuela Iezzi; Michela Spadaro; Piero Musiani; Carla De Giovanni; Pier Luigi Lollini; Stefania Lanzardo; Guido Forni; Remo Sanges; Stefania Crispi; Pasquale De Luca; Raffaele Calogero; Federica Cavallo
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

8.  Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene.

Authors:  P L Lollini; M C Bosco; F Cavallo; C De Giovanni; M Giovarelli; L Landuzzi; P Musiani; A Modesti; G Nicoletti; G Palmieri
Journal:  Int J Cancer       Date:  1993-09-09       Impact factor: 7.396

9.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 10.  A new model for ductal carcinoma in situ suggests strategies for treatment.

Authors:  William John Gullick
Journal:  Breast Cancer Res       Date:  2002-07-19       Impact factor: 6.466

View more
  22 in total

1.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

2.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Authors:  Elisa Ciraolo; Manuela Iezzi; Romina Marone; Stefano Marengo; Claudia Curcio; Carlotta Costa; Ornella Azzolino; Cristiano Gonella; Cristina Rubinetto; Haiyan Wu; Walter Dastrù; Erica L Martin; Lorenzo Silengo; Fiorella Altruda; Emilia Turco; Letizia Lanzetti; Piero Musiani; Thomas Rückle; Christian Rommel; Jonathan M Backer; Guido Forni; Matthias P Wymann; Emilio Hirsch
Journal:  Sci Signal       Date:  2008-09-09       Impact factor: 8.192

4.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

5.  Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy; Joan Garrett; Sharad V Rawale; Daniele Vicari; Jennifer M Thurmond; Tammy Lamb; Aruna Mani; Yahaira Kane; Catherine R Balint; Donald Chalupa; Gregory A Otterson; Charles L Shapiro; Jeffrey M Fowler; Michael R Grever; Tanios S Bekaii-Saab; William E Carson
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

6.  Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.

Authors:  Elena Quaglino; Simona Rolla; Manuela Iezzi; Michela Spadaro; Piero Musiani; Carla De Giovanni; Pier Luigi Lollini; Stefania Lanzardo; Guido Forni; Remo Sanges; Stefania Crispi; Pasquale De Luca; Raffaele Calogero; Federica Cavallo
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

7.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.

Authors:  Cecilia Melani; Sabina Sangaletti; Francesca M Barazzetta; Zena Werb; Mario P Colombo
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

8.  2011: the immune hallmarks of cancer.

Authors:  Federica Cavallo; Carla De Giovanni; Patrizia Nanni; Guido Forni; Pier-Luigi Lollini
Journal:  Cancer Immunol Immunother       Date:  2011-01-26       Impact factor: 6.968

9.  An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention.

Authors:  Federica Cavallo; Annalisa Astolfi; Manuela Iezzi; Francesca Cordero; Pier-Luigi Lollini; Guido Forni; Raffaele Calogero
Journal:  BMC Bioinformatics       Date:  2005-12-01       Impact factor: 3.169

Review 10.  Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.

Authors:  Raffaele Adolfo Calogero; Francesca Cordero; Guido Forni; Federica Cavallo
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.